IDEAYA Proclaims Pricing of Public Providing By Investing.com

SOUTH SAN FRANCISCO, Calif., July 9, 2024 /PRNewswire/ — IDEAYA Biosciences (NASDAQ:), Inc.  (Nasdaq: IDYA) right this moment introduced the pricing of an underwritten public providing of frequent inventory and pre-funded warrants. IDEAYA is promoting 7,228,572 shares of frequent inventory and pre-funded warrants to buy 285,715 shares of frequent inventory within the providing. The shares of frequent inventory are being offered at a public providing worth of $35.00 per share, earlier than underwriting reductions and commissions, and the pre-funded warrants are being offered at a public providing worth of $34.9999 per pre-funded warrant. The train worth of the pre-funded warrants is $0.0001 per share. As well as, IDEAYA has granted the underwriters a 30-day choice to buy as much as an extra 1,127,142 shares of its frequent inventory on the public providing worth per share, earlier than underwriting reductions and commissions. The mixture gross proceeds to IDEAYA from this providing are anticipated to be roughly $263,000,000, earlier than deducting underwriting reductions and commissions and different providing bills, and excluding the train of any pre-funded warrants. The providing is anticipated to shut on or about July 11, 2024, topic to the satisfaction of customary closing situations.

J.P. Morgan, Goldman Sachs & Co (NYSE:). LLC, Jefferies and RBC Capital Markets are performing as joint book-running managers for the providing.

The securities described above are being provided by IDEAYA pursuant to an routinely efficient shelf registration assertion on Type S-3 that was beforehand filed with the  U.S. Securities and Trade Fee,  or the SEC. The providing is being made solely by way of a written prospectus and prospectus complement that type part of the registration assertion, copies of which can be obtained, when accessible, by request from: J.P. Morgan, by mail at J.P. Morgan Securities LLC, c/o Broadridge Monetary Options (NYSE:), 1155 Lengthy Island Avenue, Edgewood, NY 11717, or by electronic mail at prospectus-eq_fi@jpmorganchase.com and postsalemanualrequests@broadridge.com; Goldman Sachs & Co. LLC by mail at Goldman Sachs & Co. LLC, Consideration: Prospectus Division, 200 West Road,  New York, NY  10282, or by phone at 866-471-2526, or by electronic mail at  prospectus-ny@ny.electronic mail.gs.com; Jefferies, by mail at Jefferies LLC, Consideration: Fairness Syndicate Prospectus Division, 520 Madison Avenue, New York, NY 10022, or by phone at 877-547-6340 or 877-821-7388, or by electronic mail at Prospectus_Department@Jefferies.com; or RBC Capital Markets, by mail at RBC Capital Markets, LLC, Consideration: Fairness Capital Markets, 200 Vesey Road, 8^th Ground, New York, NY 10281, or by phone at 877-822-4089, or by electronic mail at equityprospectus@rbccm.com.

This press launch shall not represent a suggestion to promote or a solicitation of a suggestion to purchase these securities, nor shall there be any sale of those securities in any state or different jurisdiction wherein such provide, solicitation or sale could be illegal previous to the registration or qualification beneath the securities legal guidelines of any such state or different jurisdiction.

About IDEAYA Biosciences

IDEAYA is a precision medication oncology firm dedicated to the invention and improvement of focused therapeutics for affected person populations chosen utilizing molecular diagnostics. IDEAYA’s method integrates capabilities in figuring out and validating translational biomarkers with drug discovery to pick affected person populations most probably to profit from its focused therapies. IDEAYA is making use of its analysis and drug discovery capabilities to artificial lethality “ which represents an rising class of precision medication targets.

Authorized Discover Relating to Ahead-Trying Statements

This press launch comprises forward-looking statements. All statements apart from statements of historic information contained herein, together with with out limitation statements concerning the anticipated closing of the general public providing, are forward-looking statements reflecting the present beliefs and expectations of administration made pursuant to the secure harbor provisions of the Non-public Securities Litigation Reform Act of 1995. Such forward-looking statements contain substantial dangers and uncertainties that might trigger IDEAYA’s preclinical and scientific improvement applications, future outcomes, efficiency or achievements to vary considerably from these expressed or implied by the forward-looking statements. Such dangers and uncertainties embody, amongst others, dangers and uncertainties associated to market situations and the satisfaction of closing situations associated to the proposed public providing, the uncertainties inherent within the drug improvement course of, together with IDEAYA’s applications’ early stage of improvement, the method of designing and conducting preclinical and scientific trials, critical antagonistic occasions, undesirable unwanted effects or sudden traits of drug improvement candidates the regulatory approval processes, the timing of regulatory filings, the challenges related to manufacturing drug merchandise, IDEAYA’s skill to efficiently set up, defend and defend its mental property and different issues that might have an effect on the sufficiency of current money to fund operations. IDEAYA undertakes no obligation to replace or revise any forward-looking statements. For an extra description of the dangers and uncertainties that might trigger precise outcomes to vary from these expressed in these forward-looking statements, in addition to dangers regarding the enterprise of IDEAYA usually, see IDEAYA’s present and future filings with the SEC, together with its Annual Report on Type 10-Ok filed on February 20, 2024, Quarterly Report on Type 10-Q filed on Could 7, 2024 and preliminary prospectus complement associated to the proposed public providing.

Investor and Media Contact
IDEAYA BiosciencesAndres Ruiz BrisenoSenior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com